EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effects of antibodies to infliximab on safety and efficacy of infliximab treatment in patients with Crohns disease



Effects of antibodies to infliximab on safety and efficacy of infliximab treatment in patients with Crohns disease



Gastroenterology 122(4 Suppl 1): A 613-A 614, April




(PDF emailed within 1 workday: $29.90)

Accession: 034814955

Download citation: RISBibTeXText



Related references

Effect of antibodies to infliximab on infusion reaction and clinical response in patients with fistulizing crohns disease receiving maintenance treatment with infliximab. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1598, 2003

Relationship of antibodies to infliximab to duration of response and infusion reactions for crohns disease patients receiving episodic infliximab retreatment in accent i. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1586, 2003

Efficacy and safety of infliximab in 221 Crohns disease patients. American Journal of Gastroenterology 95(9): 2640-2641, September, 2000

Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease. Danish Medical Journal 60(4): B4616-B4616, 2014

Safety and efficacy of infliximab therapy in HIV patients with Crohns disease. Gastroenterology 122(4 Suppl 1): A 616, April, 2002

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 37(12): 1172-1183, 2013

Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683. Expert Opinion on Biological Therapy 16(10): 1311-1312, 2016

Efficacy and safety of infliximab treatment for refractory and fistulizing Crohns disease in a Dutch expanded access program. Gastroenterology 118(4 Suppl 2 Part 1): AGA A588, April, 2000

Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. Journal of Crohn's & Colitis 8(8): 881-889, 2015

Efficacy of infliximab in the treatment of korean patients with crohns disease. Korean Journal of Gastroenterology 54(2): 108-116, 2009

Treatment with infliximab in patients with fistulizing crohns disease efficacy and predictors of response. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1369, 2003

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Research & Therapy 13(3): R105-R105, 2012

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. Plos One 10(12): E0144900-E0144900, 2016

Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. Journal of Crohn's & Colitis 9(7): 525-531, 2016

Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring. Annals of Clinical Biochemistry 53(Pt 4): 477-484, 2015